Rehospitalization, Treatment, and Resource Use After Inpatient Admission for Achalasia in the USA.


Journal

Digestive diseases and sciences
ISSN: 1573-2568
Titre abrégé: Dig Dis Sci
Pays: United States
ID NLM: 7902782

Informations de publication

Date de publication:
12 2021
Historique:
received: 13 07 2020
accepted: 08 12 2020
pubmed: 3 1 2021
medline: 15 12 2021
entrez: 2 1 2021
Statut: ppublish

Résumé

Readmission for achalasia treatment is associated with significant morbidity and cost. Factors predictive of readmission would be useful in identifying patients at risk. We performed a retrospective study using the Nationwide Readmission Database for the year 2016 and 2017. We collected data on hospital readmissions of 17,848 adults who were hospitalized for achalasia and discharged. The 30-day readmission rate as well as the primary cause, mortality rate, in-hospital adverse events, and total hospitalization charges were examined. A cox multivariate regression model was used to identify independent risk factors for 30-day readmission, including the surgical or endoscopic treatment used during the index admission. From 2016 to 2017, the 30-day readmission rate for index admission with achalasia was 15.2%. Of these 15.2%, 34% were readmitted with persistent symptoms of achalasia or treatment-related complications. Older age, higher comorbidity index, possessing private insurance, and those with either pneumatic balloon dilation or no endoscopic/surgical treatment showed higher odds of readmission on multivariate analysis. Those treated with laparoscopic Heller myotomy (LHM) or peroral endoscopic myotomy (POEM) showed lower odds of readmission. There was no difference in rates of readmission between those undergoing POEM or LHM, but mortality rate for readmission was significantly higher for the LHM group. The in-hospital mortality rate and length of stay were significantly higher for readmissions (p < 0.01) than the index admissions. Three in 20 patients admitted with achalasia are likely to be readmitted within 30 days of their initial hospitalization, a number which can be higher in untreated patients and in those with multiple comorbidities. Rehospitalizations bear a higher mortality rate than the initial admission and present a burden to the healthcare system.

Identifiants

pubmed: 33386520
doi: 10.1007/s10620-020-06775-5
pii: 10.1007/s10620-020-06775-5
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

4149-4158

Informations de copyright

© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Références

Cohen S. Motor disorders of the esophagus. N Engl J Med. 1979;301:184–192.
doi: 10.1056/NEJM197907263010404
O’Neill OM, Johnston BT, Coleman HG. Achalasia: a review of clinical diagnosis, epidemiology, treatment and outcomes. World J Gastroenterol. 2013;19:5806–5812.
doi: 10.3748/wjg.v19.i35.5806
Sadowski DC, Ackah F, Jiang B, Svenson LW. Achalasia: incidence, prevalence and survival. A population-based study. Neurogastroenterol Motil. 2010;22:e256–e261.
doi: 10.1111/j.1365-2982.2010.01511.x
Eckardt VF, Köhne U, Junginger T, Westermeier T. Risk factors for a diagnostic delay in achalasia. Dig Dis Sci. 1997;42:580–585. https://doi.org/10.1023/A:1018855327960 .
doi: 10.1023/A:1018855327960 pubmed: 9073142
Inoue H, Minami H, Kobayashi Y, et al. Peroral endoscopic myotomy (POEM) for esophageal achalasia. Endoscopy. 2010;42:265–271.
doi: 10.1055/s-0029-1244080
Von Renteln D, Fuchs KH, Fockens P, et al. Peroral endoscopic myotomy for the treatment of achalasia: an international prospective multicenter study. Gastroenterology. 2013;145(2):309–11.e1, 3.
Inoue H, Sato H, Ikeda H, et al. Per-oral endoscopic myotomy: a series of 500 patients. J Am Coll Surg. 2015;221:256–264.
doi: 10.1016/j.jamcollsurg.2015.03.057
Teitelbaum EN, Soper NJ, Santos BF, et al. Symptomatic and physiologic outcomes one year after peroral esophageal myotomy (POEM) for treatment of achalasia. Surg Endosc. 2014;28:3359–3365.
doi: 10.1007/s00464-014-3628-1
Familiari P, Gigante G, Marchese M, et al. Peroral endoscopic myotomy for esophageal achalasia: outcomes of the first 100 patients with short-term follow-up. Ann Surg. 2016;263:82–87.
doi: 10.1097/SLA.0000000000000992
Kumbhari V, Familiari P, Bjerregaard NC, et al. Gastroesophageal reflux after peroral endoscopic myotomy: a multicenter case-control study. Endoscopy. 2017;49:634–642.
doi: 10.1055/s-0043-105485
Kocher RP, Adashi EY. Hospital readmissions and the affordable care act. JAMA. 2011;306:1794–1795.
doi: 10.1001/jama.2011.1561
Healthcare Cost and Utilization Project (HCUP) 2013 introduction to the NRD. Agency for Healthcare Research and Quality; Rockville, MD: Dec, 2015. Accessed 15 Jan 2020.
Gupta K, Khan A, Kumar M, Sawalha K, Abozenah M, Singhania R. Readmissions rates after myocardial infarction for gastrointestinal bleeding: a national perspective. Dig Dis Sci (Epub ahead of print). 2020;. https://doi.org/10.1007/s10620-020-06315-1 . PMID: 32436123.
doi: 10.1007/s10620-020-06315-1
Poupore AK, Stem M, Molena D, Lidor AO. Incidence, reasons, and risk factors for readmission after surgery for benign distal esophageal disease. Surgery. 2016;160:599–606.
doi: 10.1016/j.surg.2016.04.037
Ali AB, Khan NA, Nguyen DT, et al. Robotic and per-oral endoscopic myotomy have fewer technical complications compared to laparoscopic Heller myotomy. Surg Endosc. 2019;34:1432–2218.
Ehlers AP, Oelschlager BK, Pellegrini CA, et al. Achalasia treatment, outcomes, utilization, and costs: a population-based study from the United States. J Am Coll Surg. 2017;225:380–386.
doi: 10.1016/j.jamcollsurg.2017.05.014
Aiolfi A, Bona D, Riva CG, et al. Systematic review and bayesian network meta-analysis comparing laparoscopic heller myotomy, pneumatic dilatation, and peroral endoscopic myotomy for esophageal achalasia. J Laparoendosc Adv Surg Tech A. 2020;30:147–155. https://doi.org/10.1089/lap.2019.0432 .
doi: 10.1089/lap.2019.0432 pubmed: 31364910
Boeckxstaens GE, Annese V, des Varannes SB, et al. Pneumatic dilation versus laparoscopic Heller’s myotomy for idiopathic achalasia. N Engl J Med. 2011;364:1807–1816.
doi: 10.1056/NEJMoa1010502
Newberry C, Vajravelu RK, Pickett-Blakely O, Falk G, Yang YX, Lynch KL. Achalasia patients are at nutritional risk regardless of presenting weight category. Dig Dis Sci. 2018;63:1243–1249. https://doi.org/10.1007/s10620-018-4985-8 . PMID: 29468378.
doi: 10.1007/s10620-018-4985-8 pubmed: 29468378
Li H, Peng W, Huang S, et al. The 2 years’ long-term efficacy and safety of peroral endoscopic myotomy for the treatment of achalasia: a systematic review. J Cardiothorac Surg. 2019;. https://doi.org/10.1186/s13019-018-0811-9 .
doi: 10.1186/s13019-018-0811-9 pubmed: 31888760 pmcid: 6937636
Patti MG, Pellegrini CA. Esophageal achalasia 2011: pneumatic dilatation or laparoscopic myotomy? J Gastrointest Surg. 2012;16(4):870–873.
doi: 10.1007/s11605-011-1694-4
Minami H, Inoue H, Haji A, et al. Per-oral endoscopic myotomy: emerging indications and evolving techniques. Dig Endosc. 2015;26:175–181.
doi: 10.1111/den.12328
Schlottmann F, Luckett DJ, Fine J, et al. Laparoscopic Heller myotomy versus peroral endoscopic myotomy (POEM) for achalasia: a systematic review and meta-analysis. Ann Surg. 2018;267(3):451–460.

Auteurs

Kamesh Gupta (K)

Department of Internal Medicine, UMMS-Baystate Medical Center, 759, Chestnut St, Springfield, MA, 01199, USA. Kameshg9@gmail.com.

Ahmad Khan (A)

Department of Medicine, West Virginia University- Charleston Division, Charleston, WV, USA.

Jean Chalhoub (J)

Department of Gastroenterology, UMMS-Baystate Medical Center, Springfield, MA, USA.

Kevin Groudan (K)

Department of Internal Medicine, UMMS-Baystate Medical Center, 759, Chestnut St, Springfield, MA, 01199, USA.

David Desilets (D)

Department of Gastroenterology, UMMS-Baystate Medical Center, Springfield, MA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH